About Prof. Salwa Ahmed Elgebaly
Current position
Dr. Salwa Elgebaly is the founder and Chief Executive Officer (CEO) of the Biotech Company Nour Heart, Inc. established in Hartford, CT. The aim of the Company is to develop the new cardioprotective drug Cyclocreatine Phosphate for patients with ischemic heart diseases and the cardiac-derived inflammatory mediator Nourin as an early biomarker of patients with ischemic heart disease. She is the Inventor of nine (9) Patents Issued by the U.S. Patent Office and one pending application.